Taspoglutide, a once-weekly glucagon-like peptide1 analogue, vs. insulin glargine titrated to target in patients with Type2 diabetes: An open-label randomized trial

1. Nauck, M.
2. Horton, E.
3. Andjelkovic, M.
4. Ampudia-Blasco, F.J.
5. Parusel, C.T.
6. Boldrin, M.
7. Balena, R.